title: Mesenchymal stromal cells isolated from children with systemic juvenile idiopathic arthritis suppress innate and adaptive immune responses.
abstract: OBJECTIVE
  Infusion of mesenchymal stromal cells (MSCs) has been reported to be an effective treatment modality for acute graft-versus-host disease, and MSCs have been considered for use in the treatment of patients with autoimmune diseases. Before contemplating clinical studies with MSCs in patients with systemic juvenile idiopathic arthritis (sJIA), the immunomodulatory capacity of MSCs in this setting needs to be explored. A comparative analysis of bone marrow-derived MSCs from children with sJIA and healthy pediatric controls was performed.
  
  
  METHODS
  MSCs were successfully expanded from 11 patients with sJIA and 10 controls. The phenotype, differentiation and immunomodulatory capacity of these MSCs were compared. The effect of immunosuppressive drugs on MSC function was also investigated.
  
  
  RESULTS
  MSCs from patients with sJIA and controls showed no differences in their suppressive effect using control peripheral blood mononuclear cells. Furthermore, the suppression of the response of peripheral blood mononuclear cells from patients with sJIA by autologous sJIA MSCs and allogeneic control MSCs was comparable. The immunosuppressive effect of both groups of MSCs was diminished in the presence of indomethacin (P < 0.05). MSCs from patients with sJIA and controls suppressed interleukin-2-induced natural killer cell activation to a similar extent. In addition, MSCs of patients with sJIA and controls inhibited the differentiation of monocytes to dendritic cells.
  
  
  CONCLUSIONS
  This is the first explorative study in a significant cohort of patients with sJIA to evaluate the effect of MSCs on adaptive and innate immune responses. The comparable immunosuppressive characteristics of MSCs derived from patients with sJIA to age-matched controls support the potential use of patient-derived MSCs in the treatment of sJIA.
authors: Department of Paediatrics, Leiden University Medical Centre, Leiden, The Netherlands.
authors: Friso G J
authors: FG
authors: Calkoen
authors: Danielle M C
authors: DM
authors: Brinkman
authors: Carly
authors: C
authors: Vervat
authors: Monique M
authors: MM
authors: van Ostaijen-Ten Dam
authors: Rebecca
authors: R
authors: Ten Cate
authors: Maarten J D
authors: MJ
authors: van Tol
authors: Lynne M
authors: LM
authors: Ball
mesh_terms: D056704:Adaptive Immunity; D001171:Arthritis, Juvenile / Q000378:metabolism / Q000503:physiopathology; D002648:Child; D002675:Child, Preschool; D003713:Dendritic Cells / Q000166:cytology / Q000378:metabolism; D005260:Female; D006801:Humans; D007113:Immunity, Innate; D007165:Immunosuppression Therapy; D007213:Indomethacin / Q000008:administration & dosage; D007223:Infant; D007231:Infant, Newborn; D007694:Killer Cells, Natural / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000166:cytology* / Q000276:immunology / Q000378:metabolism; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology / Q000378:metabolism
chemical_list: D007213:Indomethacin